Single case reports of long-lasting responses in leukaemia treatments led to rapid clinical development and registration of two CAR-T cell products which are now available in clinical practice in some parts of the world. Now approved in Australia, the means of action of this class of treatment is truly original and presents with specific toxicities that require special management approaches. Recent developments suggest we are on the brink of a new era in treatment of haematological malignancies, and potentially solid tumours.
During this Monday Lunch Live you will also hear from cancer survivor Finnian Kenny who was 46 when diagnosed with Double Hit Lymphoma. Finnian underwent treatments including various chemotherapies, auto stem cell transplant and radiotherapy. After many failed attempts, Finnian was fortunate to be accepted on a CAR T Cell Trial and survived to tell the tale. Finnian is now 50 and has been in remission for almost 2 years. He is living life to the full, working hard, taking those bucket list trips and making the most of life.
Michael Dickinson, Haematologist
Disease Group Lead in Aggressive Lymphoma
Peter MacCallum Cancer Centre and Royal Melbourne Hospital
CART-Physician, National Centre of Excellence for Cellular Immunotherapy
Michael Dickinson leads the Aggressive Lymphoma team within Clinical Haematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital. He runs a busy lymphoma clinic seeing patients with new diagnoses, but also patients with relapsed and refractory therapy requiring experimental treatments. Michael is the Principal Investigator of several first-in-human trials and chimeric antigen receptor T-cell trials that focus on harnessing the immune system to target cancer. He has been heavily involved in setting up the new CAR-T service at Peter Mac. Michael earned his medical degree at the University of Western Australia and did professional training in at the Royal Brisbane Hospital and the Royal Marsden Hospital, and at Peter Mac. His higher degree was in the field of epigenetic therapies and phase-1 trial design.
Can't attend in person? Register for Webinar